High expression of polo-like kinase 4 predicts worse progression-free survival in diffuse large B cell lymphoma patients treated with R-CHOP.

ABSTRACT:

Background

Polo-like kinase 4 (PLK4) has been shown to be a tumor-promoting factor with multiple impacts on cancer growth, invasiveness, and treatment sensitivity. The current study aimed to investigate the expression of PLK4 in diffuse large B-cell lymphoma (DLBCL) versus control tissues and its relationship with disease features and prognosis in DLBCL patients undergoing R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) treatment.

Methods

Ninety-seven DLBCL patients who received R-CHOP treatment were retrospectively included, and the lesion tissue was retrieved and subjected to quantitative polymerase chain reaction (qPCR) for PLK expression determination. Another 30 control tissues (reactive lymphoid tissue) were also subjected to qPCR.

Res

SUBMITTER: Xu D 

PROVIDER: S-EPMC12522357 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature